// App-Quantinova.ai

: CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes

Researchers

Presenter

  • Alberto Papi

Principal Investigators

  • Neil Barnes

  • Andrew Fowler

  • Huib Kerstjens

  • Edward Kerwin

  • David Mannino

  • Robert Nathan

  • Ian Pavord

  • Emillio Pizzichini

  • David Slade

  • Agne Zarankaite

  • John Oppenheimer

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Rutgers New Jersey Medical School, Newark, NJ, United States of America

  • NIH/NIEHS, Research Triangle Park, United States of America

  • GSK, Brentford, Middlesex, United Kingdom,

  • Crisor LLC Research, Clinical Research Institute of Southern Oregon, Medford, OR, United States of America

  • Asthma & Allergy Associates, P.C. and Research Center (at the time of the study), Colorado Springs, CO, United States of America

  • University of Ferrara, Ferrara, Italy

  • University of Kentucky & GSK (at the time of the study), Lexington, KY & Research Triangle Park, NC, United States of America

  • GSK & Federal University of Santa Catarina, Brentford, Middlesex & Santa Catarina, United Kingdom

  • GSK & William Harvey Institute, Barts and The London School of Medicine and Dentistry, Brentford, Middlesex & London, United Kingdom

  • University of Groningen and University Medical Center Groningen, Groningen, Netherlands

Locations

  • United States

  • Italy

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Umeclidinium

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Parallel Group

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved